Skip Navigation Links
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Overall Recruitment Status: Active, enrollment completed
Official Title
A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer
Region Sponsors
California - Northern
Aravive Biologics, Inc.
Acronym KP IRB No.
Study Type Phase
Clinical Trial Phase II
Study Population Description
(Adult, Older Adult) Female with platinum-resistant recurrent ovarian cancer.
The primary objective of this study is to evaluate the safety and tolerability of AVB-S6-500 (AVB) in c ombination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in platinum resistant recurrent ovarian cancer patients.
Detailed Description
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.
Gender Age Limit
Female 18 years & older
Inclusion Criteria
  • Age 18 years or older
  • Histologically confirmed and documented recurrent ovarian, fallopian tube, and peritoneal cancer
  • Platinum resistant disease, defined as progression within = <6 months from completion of most recent regimen and calculated from the date of the last administered dose of platinum therapy
  • Must have available archived tumor tissue OR if archived tissue is not available, willing to provide a fresh tumor biopsy
  • Must have radiologic imaging with a computerized tomography (CT) scan or magnetic resonance imaging (MRI) within 4 weeks of enrollment
  • Received at least 1 but not more than 3 therapy regimens, not including maintenance or adjuvant therapy
  • Must have ovarian cancer that is measurable according to RECIST 1.1
  • ECOG performance status of 0-1
  • Normal gastrointestinal (GI), bone marrow, liver and kidney function
  • At least 28 days between termination of prior anti-cancer or hormonal therapy and administration of AVB-S6-500
Exclusion Criteria
  • Primary platinum-refractory disease (defined as progression during the first platinum regimen)
  • Currently being treated with concurrent anti-cancer therapy or any other interventional treatment or trial
  • Received prior therapy with Pac or PLD in the recurrent setting, depending on physician-chosen chemotherapy for this study
  • Significant cardiac disease history
  • Has other prior or concurrent malignancy within the past 5 years except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
  • Symptomatic CNS metastasis or metastases
  • Serious active infection requiring IV antibiotics and/or hospitalization at study entry
  • Has active, suspected, or previously documented autoimmune disease, defined as requiring systemic treatment
  • Has known human immune deficiency (HIV) syndrome, hepatitis B, or hepatitis C

Keywords and/or Specific Medical Conditions
  • Adnexal Diseases
  • Molecular Mechanisms of Pharmacological Action
  • Albumin-Bound Paclitaxel
  • Neoplasms
  • Antibiotics, Antineoplastic
  • Neoplasms by Histologic Type
  • Antimitotic Agents
  • Neoplasms by Site
  • Antineoplastic Agents
  • Neoplasms, Glandular and Epithelial
  • Antineoplastic Agents, Phytogenic
  • Ovarian cancer
  • AVB500-OC-002
  • Ovarian Diseases
  • Doxorubicin
  • Ovarian Neoplasms
  • Endocrine Gland Neoplasms
  • Paclitaxel
  • Endocrine System Diseases
  • Platinum resistant
  • Enzyme Inhibitors
  • Topoisomerase II Inhibitors
  • Genital Diseases, Female
  • Topoisomerase Inhibitors
  • Genital Neoplasms, Female
  • Tubulin Modulators
  • Gonadal Disorders
  • Urogenital Neoplasms
  • Liposomal doxorubicin
  • Oncology (Adult)
  • Mitosis Modulators
KP Clinical Facility
  • Diablo Medical Center-Walnut Creek
  • Hayward Medical Center
  • Oakland Medical Center
  • Roseville Medical Center
  • Sacramento Medical Center
  • San Francisco Medical Center
  • Santa Clara Medical Center-Homestead
  • Vallejo Medical Center
Clinical Area
  • Oncology (Adult)

Principal Investigator:
Michael Bookman, MD
Contact Information:
- Desiree Goldstein
-Vallejo Medical Center

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: